Neumeier Poma Investment Counsel’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-151,810
| Closed | -$4.44M | – | 45 |
|
|
2024
Q1 | $4.44M | Sell |
151,810
-15,360
| -9% | -$449K | 0.41% | 40 |
|
|
2023
Q4 | $5.64M | Sell |
167,170
-98,450
| -37% | -$3.32M | 0.5% | 39 |
|
|
2023
Q3 | $8.15M | Buy |
265,620
+15,700
| +6% | +$482K | 0.8% | 40 |
|
|
2023
Q2 | $10M | Sell |
249,920
-7,600
| -3% | -$305K | 0.92% | 38 |
|
|
2023
Q1 | $10.5M | Sell |
257,520
-19,070
| -7% | -$778K | 0.98% | 38 |
|
|
2022
Q4 | $10.7M | Buy |
276,590
+12,275
| +5% | +$474K | 0.99% | 40 |
|
|
2022
Q3 | $14.1M | Sell |
264,315
-85,385
| -24% | -$4.54M | 1.39% | 32 |
|
|
2022
Q2 | $20.4M | Buy |
349,700
+32,275
| +10% | +$1.88M | 1.59% | 31 |
|
|
2022
Q1 | $24.2M | Sell |
317,425
-10,425
| -3% | -$796K | 1.63% | 32 |
|
|
2021
Q4 | $19.7M | Sell |
327,850
-294,250
| -47% | -$17.7M | 1.1% | 36 |
|
|
2021
Q3 | $34.8M | Sell |
622,100
-24,430
| -4% | -$1.37M | 2.07% | 28 |
|
|
2021
Q2 | $39.2M | Buy |
646,530
+43,670
| +7% | +$2.65M | 2.3% | 19 |
|
|
2021
Q1 | $42.3M | Buy |
602,860
+5,715
| +1% | +$401K | 2.54% | 16 |
|
|
2020
Q4 | $35.7M | Buy |
597,145
+165,445
| +38% | +$9.9M | 2.37% | 19 |
|
|
2020
Q3 | $26M | Buy |
+431,700
| New | +$26M | 2.14% | 21 |
|